Leman Biotech, a spin-off company of EPFL, co-founded by Prof. Li Tang (Head of Laboratory of Biomaterials for Immunoengineering), aims at developing and commercializing new metabolic cancer immunotherapies. Recently, the start-up company closed a US$11 million angel financing round. The money raised will enable it to accelerate the preclinical studies of biomolecule and cell based therapies and prepare for entering clinical trials. The headquarter of the company is now in Shenzhen, a highly vibrant city with the highest number of start-ups per head of population in China. Currently, Leman Biotech is launching a new drug discovery center in Lausanne, Switzerland, to initiate clinical trials in Europe.
Leman Biotech Lausanne SA
Route de la Corniche 6